New research reveals critical gaps in treatment for advanced non–small cell lung cancer (NSCLC), emphasizing the need for ...

A new review was published in Volume 16 of Oncotarget on June 25, 2025, titled "Challenges and resistance mechanisms to EGFR ...

DelveInsight’s Refractory Metastatic Melanoma pipeline report depicts a robust space with 4+ active players working to ...

Results from the Phase III KEYNOTE-689 trial show that adding perioperative Keytruda (pembrolizumab) to standard-of-care radiotherapy improves event-free survival in patients with resectable, locally ...

The latest advancements in upper gastrointestinal (GI) cancer treatment include early detection tools, immunotherapy, ...

A team of researchers at the UCLA Health Jonsson Comprehensive Cancer Center has identified a potential new strategy to ...

We report, for the first time to the best of our knowledge, the largest cohort of serial hs-TnI surveillance in patients diagnosed with cancer and treated with ICIs therapies,” the researchers wrote.

Total aggregate value of the drugs generating the highest sales in 2024 rose 6.5% vs. 2023, and jumped 53% over five years.

In eight tumors where patients failed immune checkpoint inhibitor (ICI) treatment, Plinabulin + radiation + PD-1 inhibitors demonstrated ...

AEMD READ THE FULL AEMD RESEARCH REPORT Assessing if the Hemopurifier in conjunction with standard of care treatment can increase the population that can benefit from combined treatment Aethlon ...

A new review was published in Volume 16 of Oncotarget on June 17, 2025, titled "Optimizing enfortumab vedotin plus ...